PredictImmune, Addenbrooke's Hospital Sign Agreement to Provide IBD Diagnostic in UK, Ireland

Apr 02, 2019

NEW YORK (GenomeWeb) – PredictImmune announced today that it has entered a commercial agreement with Addenbrooke's Hospital — part of Cambridge University Hospitals National Health Service Foundation Trust — to provide the company's PredictSure IBD prognostic assay to clinicians and gastroenterologists in the UK and Ireland.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Menu

PredictImmune, Addenbrooke's Hospital Sign Agreement to Provide IBD Diagnostic in UK, Ireland

To read the full story....

Breaking News

Local Coverage Determinations Roundup: Natera, Guardant Health, Transplant Genomics, and More

In Brief This Week: Invivoscribe, Todos Medical, Personalis, and More

FDA Approves CD Diagnostics' Test for Prosthetic Joint Infections

FDA Clears InBios International Zika Antibody Test

Beckman Coulter Life Sciences Recalls Hematology Analyzers Due to Risk of Inaccurate Results

Qiagen-Backed Firm Apis Assay Technologies Launches in Manchester Innovation Hub

Featured White Papers

Lowering RNA-seq Costs via Enzymatic rRNA Depletion with Custom, Species-specific Probes

Clinical Genomics of NTRK Fusion Detection in Cancer

Genome-Wide NIPT for Rare Chromosomal Conditions: Technical, Biological, and Clinical Considerations

Error-Corrected Sequencing to Detect Measurable Residual Disease in Post-Transplant MDS Cases

What's Popular?

FDA Clears Cepheid, Hologic CT/NG Assays for Extragenital Testing

Roche Obtains FDA Clearance for Sexually Transmitted Disease Test

Qiagen-Backed Firm Apis Assay Technologies Launches in Manchester Innovation Hub

Guardant Health Prices $319.5M Public Stock Offering

Startup Novel Microdevices Developing Rapid Point-of-Care MDx System for STIs

Sponsorships